Thus, despite the strong preclinical efficacy of targeting HH with cyclopamine derivatives in CCA, engaging novel SMO antagonizing structures that could offer more powerful mechanisms of target binding and biological action [165,166,167,168,169,170,171,172,173,174] should be properly considered for CCA studies. The gene discussed is SMO; the disease is cholangiocarcinoma.